Christopher Peetz sold $3.8M of MIRM
CHIEF EXECUTIVE OFFICER at Mirum Pharmaceuticals, Inc.. 40,985 shares at an average of $91.98, traded Mar 16, 2026, filed Mar 17, 2026.
Score components
- +25RoleCEO
- +25Trade size$3.8M at market
- +5Share of holdings soldSold 17% of holdings
- +15Cluster6 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -0.7%, 3m +5.2%, 6m -2.7%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001614740-26-000009, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 15, 2026 | MOption exercise Common Stock | +25,000 | - | - | 185,294 | Mar 17, 2026 |
| Mar 15, 2026 | MOption exercise Common Stock | +50,000 | - | - | 235,294 | Mar 17, 2026 |
| Mar 16, 2026 | SOpen-market sale Common Stock | -40,985 | $91.98 | $3.8M | 194,309 | Mar 17, 2026 |
| Mar 15, 2026 | MOption exercise Performance Restricted Stock Unitsderivative | -25,000 | $0.00 | $0 | 0 | Mar 17, 2026 |
| Mar 15, 2026 | MOption exercise Performance Restricted Stock Unitsderivative | -50,000 | $0.00 | $0 | 25,000 | Mar 17, 2026 |
Related signals
Other insiders at Mirum Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 52Moderate | Mirum Pharmaceuticals, Inc. | Eric Bjerkholt CHIEF FINANCIAL OFFICER | $978k 9,943 shares | -18% | |
| 38Weak | Mirum Pharmaceuticals, Inc. | Jolanda Howe SVP, GLOBAL CONTROLLER | $66k 658 shares | -52% | |
| 35Weak | Mirum Pharmaceuticals, Inc. | Christopher Peetz CHIEF EXECUTIVE OFFICER | $3.0M 30,000 shares | -13% | |
| 26Weak | Mirum Pharmaceuticals, Inc. | Jolanda Howe SVP, GLOBAL CONTROLLER | $264k 2,594 shares | -31% | |
| 24Weak | Mirum Pharmaceuticals, Inc. | Eric Bjerkholt CHIEF FINANCIAL OFFICER | $469k 5,000 shares | -10% | |
| 31Weak | Mirum Pharmaceuticals, Inc. | Saira Ramasastry director | $398k 3,977 shares | -100% | |
| 35Weak | Mirum Pharmaceuticals, Inc. | Christopher Peetz CHIEF EXECUTIVE OFFICER | $2.9M 30,000 shares | -13% | |
| 12Weak | Mirum Pharmaceuticals, Inc. | Saira Ramasastry director | $219k 2,000 shares | -100% | |
| 12Weak | Mirum Pharmaceuticals, Inc. | Saira Ramasastry director | $194k 2,000 shares | -100% | |
| 47Moderate | Mirum Pharmaceuticals, Inc. | Eric Bjerkholt CHIEF FINANCIAL OFFICER | $670k 7,287 shares | -13% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.